Ask EASL

In this fifth edition of the EASL DeepDive, join Christophe Bureau, Virginia Hernandez-Gea, Marika Rudler, and Manhal Izzy to gain expert insight into the selection, management, and outcomes of patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.This EASL DeepDive webinar is supported by W. L. Gore & Associates. W. L. Gore & Associates has had no input into the content of this EASL DeepDive.Learning objectivesUnderstand the criteria for selecting appropriate patients for Transjugular Intrahepatic Portosystemic Shunt (TIPS) proceduresLearn to differentiate between high-risk and low-risk patients based on clinical indicators and patient historyExplore the impact of cardiopulmonary conditions on the outcomes of TIPS procedures, and how/when to monitor for new-onset heart failure post TIPSLearn from Marika Rudler about the strategies for preventing and managing post-TIPS hepatic encephalopathy (HE)Discuss the latest research and treatments available for managing EH in TIPS patientsAll EASL DeepDive are available on EASL Campus.

This EASL Studio episode discusses cutting-edge approaches for managing bleeding varices. Explore the evolution of endoscopic therapies, the role of interventional radiology, and decision-making for high-risk gastric varices. Gain insights into EUS-guided portal pressure assessment and its impact on tailoring treatment strategies.Moderator: Debbie ShawcrossFaculty: Wim Laleman, David PatchRelated episodeS6E14: Endohepatology: The endoscopic liver gold rushAll EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency.Learning objectives:Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcoholGet a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approachLearn more about screening: who to screen and howDiscover the general unmet needs related to AAT, with an emphasis on awareness and timely diagnosisThis EASL DeepDive webinar is supported by Takeda Pharmaceuticals. Takeda Pharmaceuticals has had no input into the content of this EASL DeepDive.Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus.Learning objectivesDiscover the latest mechanistic insights relating to the occurrence of PBC symptomsLearn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritusLearn more about the current treatment options, their efficacy and limitationsGet a detailed understanding of the drugs in the pipeline for the near futureThis EASL DeepDive webinar is supported by GSK and IPSEN. GSK and IPSEN have had no input into the content of this EASL DeepDive.Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.Learning objectives:Understand the role of glucagon and glucagon-receptor in normal physiology and disease.Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into the mechanisms through which GLP-1 receptor agonists and GLP-1/GCG might affect liver pathology and metabolic regulation.Discuss and review key clinical trials and ongoing development programs.Evaluate how GLP-1RA can be integrated into current EASL-EASD-EASO CPGs, with a focus on practical applications and patient management strategies, giving potential guidance for future applications.This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 25 February 2025,  Ana Lleo, Adriaan van der Meer, Gideon Hirschfield, and Bettina Hansen explore the future of primary biliary cholangitis (PBC) treatment. Discover the emerging therapies, current challenges and personalised approaches that are shaping the management of PBC.Learning objectivesLearn more about the molecular mechanisms underlying the disease and the potential targets for drug therapyGet a good understanding of the efficacy of the current drugs and the potential added value of the upcoming second line treatments for PBC and where to position these new treatments in the treatment landscapeLearn more about the evolving concepts regarding the endpoints in clinical trials for PBCGet insights in the risk assessment of people living with PBC and criteria for second line therapy This EASL DeepDive webinar is supported by Gilead. Gilead has had no input into the content of this EASL DeepDive.Click here to see all EASL Video Podcasts on Apple Podcasts.

This episode celebrates 40 years of the Journal of Hepatology, EASL's flagship journal.Tune in to discover how far we've come—and what's next for the journal.Moderator: Thomas Berg Faculty: Paolo Angeli, Annalisa Berzigotti, Rajiv Jalan, Vlad Ratziu, Frank Tacke and Jessica Zucman-RossiAll EASL Studio Podcasts are available on EASL Campus.

Rare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies.Read the position paper: Rare primary liver cancers: An EASL position paperModerator: Thomas BergFaculty: Ruben de Kleine and Henning WegeRelated episodesS6E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyondS5E13: Basics in decision-making for liver cancer treatmentS4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceAll EASL Studio Podcasts are available on EASL Campus.

This episode of EASL Studio explores insights from the European Alcohol Health Alliance Symposium, hosted by the WHO Regional Office for Europe in collaboration with EASL. Topics include managing alcohol marketing strategies, addressing gaps in cancer-related labeling, and understanding the influence of social norms on adolescent alcohol consumption. Learn from successful alcohol policy implementations and discover how the WHO Playbook can empower advocates to protect children and reshape public health strategies for alcohol-related harm.Moderator: Shira Zelber-SagiFaculty: Frank Murray, Catherine Paradis (WHO Europe) and Debbie ShawcrossRelated episodesS7E5 Why does WHO engagement with Steatotic Liver Disease matter?S6E7 The impact of policy measure in preventing liver diseases: The Hepahealth II studyEASL Studio live from EASL Congress 2023: The battle to reduce alcohol harms… EASL's new policyS3E5 JHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EASL Campus.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects men and women differently, yet sex-based differences remain poorly explored. In the week celebrating International Women's Day, this EASL Studio episode debates the molecular, hormonal, and genetic mechanisms driving these disparities.Moderator: Saskia van MilFaculty: Sara Della Torre and Münevver DemirRelated episode: S4E9 YI Choice: Gender equality in academics — reducing the gapAll EASL Studio Podcasts are available on EASL Campus.

Tune into this EASL Studio episode to learn about the role of PET imaging in Wilson's disease. Discover how PET advances understanding, supports treatment decisions, and enhances patient care in managing this rare liver disorder.Moderator: Debbie ShawcrossFaculty: Aftab Ala, Zoe Mariño and Thomas SandahlThis EASL Studio is supported by Orphalan and Univar Solutions.EASL has received no input from Orphalan or Univar Solutions with regards to the content of this programme.Related episodesS4E15: Diagnostic and therapeutic challenges in Wilson's diseaseS4E7: Genetics in adult liver disease – missed opportunities?All EASL Studio Podcasts are available on EASL Campus.

Join this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes.Moderator: Thomas BergFaculty: Tim Greten and Anna SaborowskiThis EASL Studio is supported by Bayer.EASL has received no input from Bayer with regards to the content of this programme.Related episodes:EASL Studio S5E13: Basics in decision-making for liver cancer treatmentEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S6E9: Therapy hierarchy in HCC: A new kid on the blockAll EASL Studio Podcasts are available on EASL Campus.

Watch this EASL Studio to start navigating your research journey with essential tips on generating ideas, refining hypotheses, and crafting standout abstracts for EASL Congress. Discover how to choose the right journal, prepare a submission-ready manuscript, and boost your career visibility in hepatology.Moderator: Thomas MarjotFaculty: Marta Afonso, Emma Andersson and Paolo AngeliRelated episodesS4E20 – COST Actions: Opportunities for pan-European collaborations in liver diseasesS4E14 – EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failureS4E2 YI Choice – How to build consortia and registriesAll EASL Studio Podcasts are available on EASL Campus.

Discover the latest updates from the updated EASL Clinical Practice Guidelines on Hepatocellular Carcinoma (HCC). This episode explores key advancements, their impact on clinical practice, and how they will shape the future of HCC diagnosis, treatment, and management. Join our faculty as they break down the changes and provide practical insights for healthcare professionals.Moderator: Thomas BergFaculty: Peter Galle, Josep Llovet and Lorenza RimassaRelated episodesEASL Studio S6E4: World Cholangiocarcinoma Day: Highlighting Guidelines and Exploring the Horizon BeyondEASL Studio S6E9: Therapy Hierarchy in HCC: A New Kid on the BlockEASL Studio S5E13: Basics in Decision-Making for Liver Cancer TreatmentEASL Studio Live from EASL Congress 2024: Advances in Systemic Treatments in Liver CancerAll EASL Studio Podcasts are available on EASL Campus.

Join us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments.Moderator: Aleksander KragFaculty: Cyrielle Caussy, Sven Francque and Brian LeeThis EASL Studio is supported by Madrigal. EASL has received no input from Madrigal with regards to the content of this programme.Related episodesS7E3 – The changing face of Steatotic Liver Disease: Navigating new opportunities and emerging challengesEASL Studio at the Congress 2024: SLD nomenclature: Need for refinement?EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio from EASL Congress 2023 – Steatotic liver disease global consensus to change nomenclatureAll EASL Studio Podcasts are available on EASL Campus.

This EASL Studio showcases cutting-edge research elucidating the role of the liver in ageing and exploring its role as a regulator of health and longevity. In particular, the liver's function in modulating systemic ageing, its ability to buffer genetic and metabolic disturbances, and its influence on the progression of age-related diseases is discussed. Last but not least, panelists provides new insights into potential therapeutic strategies aimed at promoting healthy ageing by targeting liver-specific mechanisms.This episode is related to this study published in July 2024: Inhibition of IL-11 signalling extends mammalian healthspan and lifespanFaculty: Rui Castro (Moderator)Anna Mae Diehl (Faculty)Celia Martinez-Jiménez (Faculty)Related episode EASL Studio S7E8: Sarcopenia: Converting research findings into clinical practice – Are we doing enough?All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio episode examines the current relevance of Hepatic Encephalopathy (HE) and the roles of hepatologists and interventional radiologists in patient care. The discussion covers technical approaches, patient outcomes, and the expanding indications for TIPS.Tune in to:Learn about the critical roles of hepatologists and radiologists in managing HE.Understand technical factors, including TIPS procedures and their application in modern hepatology.Explore the use of TIPS for aging patients, those with variceal bleeding, and major surgery candidates.FacultyVirginia Hernández-Gea (Moderator)Dominique Thabut (Faculty)Dhiraj Tripathi (Faculty)Thomas Kröncke (Faculty)This EASL Studio is supported by an educational grant from Cook Medical. EASL has received no input from Cook Medical with regards to the content of this programme.Related episodesEASL Studio S6E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?EASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?All EASL Studio Podcasts are available on EASL Campus.

Sarcopenia, defined by a reduction in muscle mass and strength, significantly increases the risk of hospitalisation and mortality in patients with liver cirrhosis. This EASL Studio episode highlights the importance of incorporating sarcopenia assessment and management into routine clinical practice. Experts discuss the optimal timing for assessment and strategies for implementing effective interventions.FacultyFelicity Williams (Moderator)Shelley Keating (Faculty)Jennifer Lai (Faculty)Jonathan Stine (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.Key topics of discussion include:Interaction between alcohol and cardiometabolic risksStigma and its impact on patient careIdentifying at-risk patients with clinical markersEmerging therapies and research opportunitiesFacultyAleksander Krag (Moderator)Fredrik Åberg (Faculty)Maru Rinella (Faculty)Maja Thiele (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.Related episodesEASL Studio S5E9: Alcohol and the new nomenclature – A game-changer?EASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S4E3: A 360 approach to beat alcohol-related liver diseaseEASL Studio S3E5: JHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EASL Campus.

Join the experts as they explore the new updates to the liver transplantation clinical practice guidelines, and delve into the latest advancement and ongoing challenges faced in this field.Tune in to:Discover cutting-edge techniques like machine perfusion and extended criteria grafts.Learn about new transplant indications, including oncology and acute liver failure.Understand challenges in immunosuppression and the management of chronic rejection.FacultyAhmed Elsharkawy (Moderator)Didier Samuel (Faculty)Julie Heimbach (Faculty)Sarwa Darwish (Faculty)Related episodesEASL Studio S4E13: JHEP Live: Liver transplantation for alcohol-related hepatitisEASL Studio S4E6: Regenerating the liver graft with a machineEASL Studio S3E2: Liver transplantation for ACLF: Opportunities, challenges, and pitfallsEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.

This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.FacultyJeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition's activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition's activities or this EASL Studio episode.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E7: The impact of policy measure in preventing liver diseases: The Hepahealth II studyEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio S4 Special Edition 2: Promoting Liver Health: An urgent call for action at WHOEASL Studio S4E8: The central role of alcohol and food policies on liver healthAll EASL Studio Podcasts are available on EASL Campus.

This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:Compares traditional ultrasound with advanced imaging techniques.Examines AI-based approaches in patient classification.The episode concludes with a forward-looking perspective on the future management of MASLD.FacultyThomas Berg (Moderator)Timm Denecke (Faculty)Juan-Manuel Pericàs (Faculty)Valérie Vilgrain (Faculty)This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceAll EASL Studio Podcasts are available on EASL Campus.

Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.This episode of EASL Studio:Explores the updated definitions and standardisation of AKI in the context of cirrhosis.Reviews recent clinical trials, including ATTIRE and CONFIRM, and their implications for patient care.Provides a critical analysis of current and emerging strategies for managing renal dysfunction in cirrhosis.FacultyDebbie Shawcross (Moderator)Pere Gines (Faculty)Salvatore Piano (Faculty)Florence Wong (Faculty)Related episodesEASL Studio from EASL Congress 2024: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and preventionEASL Studio S6E8: Is there a role for measuring blood ammonia in patients with cirrhosis?EASL Studio S6E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?All EASL Studio Podcasts are available on EASL Campus.

Arrivederci Milano, hallo Amsterdam!FacultyAleksander Krag (Moderator)Debbie Shawcross (Moderator)Cyrielle Caussy (Faculty)Ana Lleo (Faculty)Francesco Negro (Faculty)Vlad Ratziu (Faculty)Virginia Hernández-Gea (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Education at the heart of EASL's missionFacultySven Francque (Moderator)Krista Rombouts (Faculty)Rajeshwar Mookerjee (Faculty)Henning Grønbæk (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Landmark studies at the EASL Congress 2024FacultyThomas Berg (Moderator)Rajiv Jalan (Faculty)Verena Keitel (Faculty)Frank Tacke (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - SLD nomenclature: Need for refinement?FacultyAleksander Krag (Moderator)Meena Bansal (Faculty)Sven Francque (Faculty)Alexandre Louvet (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Exploring new frontiers: The AI liver taskforce initiativeFacultyEric Trépo (Moderator)Tom Lüdde (Faculty)Jakob Kather (Faculty)Raquel Pérez-López (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Advances in systemic treatments in liver cancerFacultyJosep Llovet (Moderator)Massimo Iavarone (Faculty)Matthias Pinter (Faculty)Jessica Zucman-Rossi (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Buongiorno Milano: What not to miss during EASL Congress.FacultyAleksander Krag (Moderator)Debbie Shawcross (Faculty)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.FacultyThomas Berg (Moderator)Jordan Feld (Faculty)Norah Terrault (Faculty)Heiner Wedemeyer (Faculty)This episode is scheduled in honour of the United States' Viral Hepatitis Awareness Month.This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no input from GSK or Vir Biotechnology with regards to the content of this programme.Related episodesSeason 6, Episode 2: Why do we need HBV functional cure?Season 5, Episode 8: JHEP Live: Hepatitis Delta's Latest Debate: Updates Straight from EASL's SlateSeason 5, Episode 3: Zoonotic Hepatitis E: What's hot in 2023?EASL Studio at the EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challengesSeason 4, Episode 19: HDV: The devil becomes treatableSeason 4, Episode 1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?All EASL Studio Podcasts are available on EASL Campus.

This insightful discussion is centred on the burgeoning field of endohepatology, where advanced endoscopic techniques revolutionise hepatology practice. With this episode, explore the broad scope of endoscopic procedures (including EUS-guided liver biopsy, portal pressure measurement, and gastric varices embolisation) and their transformative impact on diagnostics and therapeutic interventions in liver disease.To learn even more about endoscopic procedures in hepatology, take a look at this study by Wim Laleman et al., published in January 2024 in the Journal of Hepatology.Faculty Wim Laleman (Moderator)Andres Cardenas (Faculty)Gavin Johnson (Faculty)Reem Sharaiha (Faculty)Related episodesSeason 6, Episode 11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?Season 3, Episode 15: Chronic portal vein thrombosis: anticoagulation and interventional radiology for all patients?Season 2, Episode 14: Elastography – The new non-invasive gold standard in portal hypertension?All EASL Studio Podcasts are available on EASL Campus.

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.FacultyAleksander Krag (Moderator)Naim Alkhouri (Faculty)Sven Francque (Faculty)Amalia Gastaldelli (Faculty)Related episodesSeason 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureSeason 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease AwarenessSeason 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizonAll EASL Studio Podcasts are available on EASL Campus.

Join us for a critical discussion on the significance of Drug and Herbal & Dietary Supplement-Induced Liver Injury (DHILI). In this episode, the speakers explore the importance of DHILI, assess recent advancements, and deliberate on the obstacles hindering further progress in addressing this pressing healthcare concern.This episode is organised in collaboration with the EASL DHILI Consortium.FacultyGuruprasad Padur Aithal (Moderator)Paul Hayashi (Faculty)Maribel Lucena (Faculty)Paul Watkins (Faculty)Related episodesSeason 4, Episode 20 – COST Actions: opportunities for pan-European collaborations in liver diseasesAll EASL Studio Podcasts are available on EASL Campus.

In this episode, experts explore the shift away from invasive measurements in assessing clinically significant portal hypertension. The speakers address the crucial data needed to enhance the reliability and applicability of these non-invasive methods and introduce several advanced elastography techniques, shaping the future of portal hypertension assessment.FacultyBogdan Procopet (Moderator)Maria Papp (Faculty)Atoosa Rabiee (Faculty)Thomas Reiberger (Faculty)Related episodeEASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?All EASL Studio Podcasts are available on EASL Campus.

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission.FacultyMarta Alonso-Peña (Moderator)Kate Jack (Faculty)Marko Korenjak (Faculty)Thomas Marjot (Faculty)Related episodeEASL Studio from EASL Congress 2023: United we stand: Global societies collaborating to beat liver disease.All EASL Studio Podcasts are available on EASL Campus.

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.FacultyBruno Sangro (Moderator)Umberto Cillo (Faculty) Helen Reeves (Faculty)María Reig (Faculty)This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.Related episodesEASL Studio S5E13: Basics in decision-making for liver cancer treatmentEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceEASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlookEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?EASL Studio S2E15: JHEP Live on the best animal model for HCC – Lost in translation?All EASL Studio Podcasts are available on EASL Campus.

In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.FacultyDebbie Shawcross (Moderator)Rajiv Jalan (Faculty)Sara Montagnese (Faculty)Elliot Tapper (Faculty)This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).Related episodesEASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinEASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?All EASL Studio Podcasts are available on EASL Campus.

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions.FacultyPatrizia Burra (Moderator)Maria Buti (Faculty)Peter Jepsen (Faculty)Shira Zelber-Sagi (Faculty)Related episodesEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio from EASL Congress 2023: The battle to reduce alcohol harms… EASL's new policyEASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S2E2: Fats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.FacultyAleksander Krag (Moderator)Aftab Ala (Faculty)Pavel Strnad (Faculty)Alice Turner (Faculty)Related episodesEASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challengesEASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of opportunities and challengesThis episode is scheduled in honour of the Rare Disease Day (29 February).All EASL Studio Podcasts are available on EASL Campus.

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?FacultyPaolo Angeli (Moderator)Guadalupe Garcia-Tsao (Faculty)Valérie Paradis (Faculty)Thomas Reiberger (Faculty)Related episodesEASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approachEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E4: JHEP Live: Is the term ‘decompensated cirrhosis' outdated?All EASL Studio Podcasts are available on EASL Campus.

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.FacultyThomas Berg (Moderator)Katie Kelley (Faculty)Daniela Sia (Faculty)Juan Valle (Faculty)This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.Related episodesEASL Studio S5E13: Basics in decision-making for liver cancer treatmentEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceEASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlookEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.

The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management.FacultyPierre-Emmanuel Rautou (Moderator)Virginia Hernández-Gea (Faculty)Patrick Kamath (Faculty)Wim Laleman (Faculty)Related episodes:EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcomeAll EASL Studio Podcasts are available on EASL Campus.

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs' current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.Don't miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!FacultySven Francque (Moderator)Willem Pieter Brouwer (Faculty)Cyrielle Caussy (Faculty)Dimitris Papamargaritis (Faculty)This episode is scheduled following the United Kingdom's National Obesity Awareness Week.Related episodes:EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?EASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S2E2: Fats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

Join us for a wrap-up of EASL Studio's season and a preview of what is to come in 2024! In this special episode, we reminisce about the year's top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health.FacultyAleksander Krag (Moderator)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)Debbie Shawcross (Faculty)All EASL Studio Podcasts are available on EASL Campus.

Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition.This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and treatment options.FacultyDebbie Shawcross (Moderator)Christian Labenz (Faculty)Steve Rodrigues (Faculty)Dominique Thabut (Faculty)This EASL Studio is supported by Norgine. EASL has received no input from Norgine with regards to the content of this programme.Related episodeEASL Studio S2E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathyAll EASL Studio Podcasts are available on EASL Campus.

With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice.FacultyTom Lüdde (Moderator)Christoph Roderburg (Faculty)Anna Saborowski (Faculty)Arndt Vogel (Faculty)This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai with regards to the content of this programme.Related episodesEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceEASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlookEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.

This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions.FacultyPalak Trivedi (Moderator)Amanda Ricciuto (Faculty)Marianne Samyn (Faculty)Christoph Schramm (Faculty)This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme.Related episodesEASL Studio S5E4: PBC: the itch we need to scratchEASL Studio from EASL Congress 2023: Challenges and opportunities for patients with PBC: Highlights from EASL Congress 2023EASL Studio S3E3: Primary biliary cholangitis: a look at the future landscape of therapy for patientsAll EASL Studio Podcasts are available on EASL Campus.

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.FacultyThomas Reiberger (Moderator)Juan Gonzalez-Abraldes (Faculty)Elisa Pose (Faculty)Jonel Trebicka (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.Related episodesEASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?EASL Studio S4E4: JHEP Live: is the term ‘decompensated cirrhosis' outdated?EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinAll EASL Studio Podcasts are available on EASL Campus.

In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases.FacultyZobair Younossi (Moderator)Laurent Castera (Faculty)Camilla Dalby Hansen (Faculty)Amalia Gastaldelli (Faculty)This episode is scheduled according to the international calendar for the World Diabetes Day (14 November).This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme.Related episodes:EASL Studio S3E7: Bugs and the liver — the role of the gut microbiome in liver diseasesEASL Studio S2E2: Fats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases.Faculty Aleksander Krag (Moderator)Juan Pablo Arab (Faculty)Alexandre Louvet (Faculty)Maru Rinella (Faculty)Related episodes:EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S3E5: JHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EASL Campus.